Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAO 510(k) Report May Recommend Splitting Up Class II, Industry Predicts

This article was originally published in The Gray Sheet

Executive Summary

Some device industry veterans predict the pending government report on FDA's 510(k) process will include criticisms of the program and may recommend subdividing Class II moderate-risk devices into two or more new categories

You may also be interested in...



GAO Drafts 510(k) Report; Talk Grows Of Pre-Market Reform Legislation In ’09

After some delay, the Government Accountability Office has drafted a report on FDA's 510(k) submissions program, which some expect will recommend reforms to the Class II, medium-risk category of devices

GAO Drafts 510(k) Report; Talk Grows Of Pre-Market Reform Legislation In ’09

After some delay, the Government Accountability Office has drafted a report on FDA's 510(k) submissions program, which some expect will recommend reforms to the Class II, medium-risk category of devices

Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar

FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel